MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation

Alsebaey, Ayman; Sabry, Ahmed; Rashed, Hanaa Said; Elsabaawy, Maha; Ragab, Amr; Aly, Rasha Abdelhafiz; Badran, Hanaa M.

doi:10.31557/apjcp.2021.22.7.2005

Cited by 11 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the research design, 38 studies were designed as retrospective studies, and four studies were conducted prospectively. Twenty-two studies were included from Japan ( 14 , 22 – 42 ), six from Korea ( 16 , 43 – 47 ), four from China ( 48 – 51 ), two from Egypt ( 52 , 53 ), two from Germany ( 15 , 54 ), two from Italy ( 55 , 56 ), one each from Netherlands, Canada, United States of America (USA), and France ( 57 – 60 ). HCC patients were treated by hepatectomy, sorafenib, lenvatinib, TACE, yttrium-90 radioembolization, RFA, or the combination of these.…”

Section: Resultsmentioning

confidence: 99%

“…SMI is the most widely used index and sarcopenia is defined as SMI < 42 cm 2 /m 2 for men and <38 cm 2 /m 2 for women based on the guideline proposed by Japan Society of Hepatology (JSH) ( 61 ). Among twenty-seven studies using SMI, eight studies used the cut-points proposed by JSH ( 14 , 22 , 32 , 35 , 42 , 45 , 49 , 52 ), six studies employed the Martin cut-points ( 41 , 53 , 55 , 57 , 58 , 60 ), four studies applied the Vledder cut-points ( 27 , 28 , 34 , 38 ), and their own cut-points were measured in other studies. HR was estimated by univariate and multivariate Cox proportional hazards regression to investigate the influence of sarcopenia on OS and/or PFS of HCC patients in the included studies.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis

Jiang

Wang

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

BackgroundSarcopenia, characterized by the loss of muscle mass, strength, and physical ability, occurs with aging and certain chronic illnesses such as chronic liver diseases and cancer. Sarcopenia is common in liver cirrhosis and hepatocellular carcinoma (HCC). Previous reports of association between sarcopenia and prognosis of HCC have been inconsistent. Therefore, the present systematic review and meta-analysis aimed to investigate the impact of sarcopenia on the survival of patients with HCC.MethodsA systematic literature search was conducted using PubMed, EMBASE, and Web of Science electronic databases from inception to May 1, 2022. We included retrospective or prospective studies investigating the association between sarcopenia and overall survival (OS) and/or progression free survival (PFS) of HCC. We applied the Quality in Prognosis Studies (QUIPS) instrument to evaluate the risk of bias and quality of included studies. The primary and secondary outcomes were the associations of sarcopenia with OS and PFS, respectively, expressed by a pooled hazard ratio (HR) and corresponding 95% confidence interval (CI). Subgroup analysis and sensitivity analysis were performed. We further evaluated the publication bias by the funnel plot and Begg’s test.ResultsA total of 42 studies comprising 8,445 patients were included. The majority of included studies were at an overall low risk of bias. The pooled prevalence of sarcopenia was 39% (95% CI: 33–45%) (n = 8,203). Sarcopenia was associated with an increased risk of shorter OS, with a pooled adjusted HR of 1.84 (95% CI: 1.62–2.09). An independent association between sarcopenia and reduced PFS was observed (HR = 1.33, 95% CI: 1.12–1.56).ConclusionThe prevalence of sarcopenia was approximately 39% among patients with HCC. Sarcopenia was independently associated with reduced OS and PFS in HCC irrespective of treatment modalities. It is imperative that interventions aimed at alleviating sarcopenia and restoring muscle mass be implemented in order to improve the survival of patients with HCC.Systematic review registration[https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022337797], identifier [CRD42022337797].

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis

Jiang

Wang

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…Recently, when body composition features, such as sarcopenia and myosteatosis, were integrated with the model for end-stage liver disease (MELD) [ 121 , 122 , 123 , 124 ] and Child–Turcotte–Pugh score (CTP) [ 125 ], they increased the accuracy of this model in predicting mortality [ 121 , 122 , 123 , 124 ] and hospital readmission [ 125 ], particularly in those with compensated advanced chronic liver disease [ 126 ].…”

Section: Sarcopeniamentioning

confidence: 99%

Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease

Musio

Perazza

Leoni

et al. 2023

IJMS

View full text Add to dashboard Cite

Chronic liver disease (CLD), including non-alcoholic fatty liver disease (NAFLD) and its advanced form, non-alcoholic steatohepatitis (NASH), affects a significant portion of the population worldwide. NAFLD is characterised by fat accumulation in the liver, while NASH is associated with inflammation and liver damage. Osteosarcopenia, which combines muscle and bone mass loss, is an emerging clinical problem in chronic liver disease that is often underappreciated. The reductions in muscle and bone mass share several common pathophysiological pathways; insulin resistance and chronic systemic inflammation are the most crucial predisposing factors and are related to the presence and gravity of NAFLD and to the worsening of the outcome of liver disease. This article explores the relationship between osteosarcopenia and NAFLD/MAFLD, focusing on the diagnosis, prevention and treatment of this condition in patients with CLD.

show abstract

“…However, there is a lack of objective quantitative indicators from body composition to supplement the comprehensive evaluation model, which has been gradually emphasized in the past decade. [3,4]…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of sarcopenic visceral obesity in hepatocellular carcinoma treated with TACE

Hou

Chen

2023

Medicine

View full text Add to dashboard Cite

Although Transartial chemoembolization (TACE) is one of the recommended treatments for hepatocellular carcinoma (HCC), there is always a dispute on the selection of the best beneficiary for treatment. We studied the prognostic value of nutritional markers, obesity, visceral obesity and sarcopenia on survival outcomes under single and different combinations. In a retrospective cohort of 235 patients with HCC at different stages, more accurate comprehensive prognostic factors were obtained by combining and comparing the multifactor hazard ratios (HR) of various parameters, including skeletal muscle index (SMI) and visceral fat index (VFI) obtained by computer tomography, laboratory index albumin-to-globulin (A/G) ratio, anthropometric body mass index (BMI) and other parameters. The study cohort was dominated by men (73.6%), with a median age of 54 years. According to the survival outcome of HCC patients, we obtained the ideal sex cutoff value of VFI: ≥40.54 cm2/m2 for males (the receiver operating characteristic curve [ROC] = 0.764, P < .001) and ≥ 43.19 cm2/m2 for females (ROC = 0.718, P < .05). According to the results of multifactor analysis, sarcopenic visceral obesity (HR = 8.35, 95% confidence intervals [CI] = [4.96, 14.05], P < .001) is more effective than any single or combined prognosis assessment, including sarcopenic dystrophy (HR = 2.70, 95% CI = [1.85, 3.95], P < .001), sarcopenic obesity (HR = 5.23, 95% CI = [3.41, 8.02], P < .001), sarcopenia (HR = 5.74, 95% CI = [3.61, 9.11], P < .001) and visceral obesity (HR = 3.44, 95% CI = [2.24, 5.27], P < .001). Sarcopenic visceral obesity, defined by SMI and VFI, is a more objective and accurate prognostic indicator of HCC.

show abstract

MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation

Cited by 11 publications

References 15 publications

Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis

Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis

Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease

Prognostic value of sarcopenic visceral obesity in hepatocellular carcinoma treated with TACE

Contact Info

Product

Resources

About